Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seock-Ah Im

Showing results (21-30 of 567) with videos related to

Pageof 57
Sort By:
BMC Gastroenterology|May 20, 2011
Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancerSun Kyung Baek, Sae-Won Han, Do-Youn Oh, et al.
European Radiology|November 30, 2015
Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary studyDong Ho Lee, Se Hyung Kim, Seock-Ah Im, et al.
Cancer Chemotherapy and Pharmacology|September 28, 2010
Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort studyDong-Yeop Shin, Sae-Won Han, Do-Youn Oh, et al.
NPJ Breast Cancer|September 5, 2024
BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?Peter Dubsky, Christian Jackisch, Seock-Ah Im, et al.
Oncology|July 5, 2012
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancerKyu-Hyoung Lim, Sae-Won Han, Do-Youn Oh, et al.
Biomolecules|October 23, 2019
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as PertuzumabJung Won Shin, Soohyun Kim, Suji Ha, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|October 10, 2023
Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast CancersIlias P Nikas, Sojung Lim, Seock-Ah Im, et al.
Psycho-Oncology|March 18, 2022
Do posttraumatic stress symptoms predict trajectories of sleep disturbance and fatigue in patients with breast cancer? A parallel-process latent growth modelEun-Jung Shim, Donghee Jeong, Dooyoung Jung, et al.
Journal of Breast Cancer|February 26, 2021
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerJee Hyun Kim, Seock Ah Im, Sung Hoon Sim, et al.
International Journal of Oncology|December 14, 2011
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutationsEunju Park, Jinah Park, Sae-Won Han, et al.
Pageof 57

Showing results (21-30 of 567) with videos related to

Sort By:
Pageof 57
BMC Gastroenterology|May 20, 2011
Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancerSun Kyung Baek, Sae-Won Han, Do-Youn Oh, et al.
European Radiology|November 30, 2015
Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary studyDong Ho Lee, Se Hyung Kim, Seock-Ah Im, et al.
Cancer Chemotherapy and Pharmacology|September 28, 2010
Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort studyDong-Yeop Shin, Sae-Won Han, Do-Youn Oh, et al.
NPJ Breast Cancer|September 5, 2024
BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?Peter Dubsky, Christian Jackisch, Seock-Ah Im, et al.
Oncology|July 5, 2012
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancerKyu-Hyoung Lim, Sae-Won Han, Do-Youn Oh, et al.
Biomolecules|October 23, 2019
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as PertuzumabJung Won Shin, Soohyun Kim, Suji Ha, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|October 10, 2023
Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast CancersIlias P Nikas, Sojung Lim, Seock-Ah Im, et al.
Psycho-Oncology|March 18, 2022
Do posttraumatic stress symptoms predict trajectories of sleep disturbance and fatigue in patients with breast cancer? A parallel-process latent growth modelEun-Jung Shim, Donghee Jeong, Dooyoung Jung, et al.
Journal of Breast Cancer|February 26, 2021
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerJee Hyun Kim, Seock Ah Im, Sung Hoon Sim, et al.
International Journal of Oncology|December 14, 2011
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutationsEunju Park, Jinah Park, Sae-Won Han, et al.
Pageof 57